PCSA
Processa Pharmaceuticals IncNASDAQ
Healthcare • Biotechnology
$1.93+4.89%
Close Nov 6, 2026
- Market cap
- $5.31M
- 1 month
- +43.0%
- 3 months
- -26.1%
- 1 year
- -90.0%
- Dividend
- No dividends on record
- Short interest
- 1.7% of float46.5K shares · settled Oct 15, 2026 · +1,022.9% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$13.44M
- Free cash flow
- -$11.47M
- Book value
- —
- Total debt
- —
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- -216.1%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Read more
Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
- Website
- processapharmaceuticals.com
- Headquarters
- Vero Beach, FL, United States
- Employees
- 12
- Listed
- Oct 10, 2017
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 3, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 14, 2026 | — | — | — | -$2.3M | -$3.3M |
| Mar 2026filed May 7, 2026 | — | — | — | -$3.3M | -$3.4M |
| Dec 2025filed Mar 18, 2026 | — | — | — | -$3.7M | -$3.4M |
| Sep 2025filed Nov 6, 2025 | — | — | — | -$3.5M | -$3.4M |
| Jun 2025filed Aug 7, 2025 | — | — | — | -$4.0M | -$3.9M |
| Mar 2025filed May 8, 2025 | — | — | — | -$2.8M | -$2.8M |
| Dec 2024filed Mar 20, 2025 | $12.5M | — | — | -$2.7M | -$2.7M |
| Sep 2024filed Oct 30, 2024 | — | — | — | -$3.4M | -$3.4M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 18, 2026 | — | — | — | -$14.0M | -$13.6M |
| Dec 2024filed Mar 20, 2025 | — | — | — | -$12.1M | -$11.9M |
| Dec 2023filed Mar 29, 2024 | — | — | — | -$11.5M | -$11.1M |
| Dec 2022filed Mar 30, 2023 | — | — | — | -$20.3M | -$27.4M |
| Dec 2021filed Mar 30, 2022 | — | — | — | -$12.1M | -$11.4M |
| Dec 2020filed Mar 25, 2021 | — | — | — | -$15.1M | -$19.0M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched PCSA. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
46,488 shares short
+42,348 shares (+1,022.9%) vs Sep 30, 2026
1.7% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
4,140 shares short
-10,855 shares (-72.4%) vs Sep 15, 2026
0.2% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
14,995 shares short
-20,954 shares (-58.3%) vs Aug 31, 2026
0.6% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
35,949 shares short
-31,370 shares (-46.6%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
67,319 shares short
-148,532 shares (-68.8%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
215,851 shares short
+112,297 shares (+108.4%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind PCSA’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 25 · reverse split
Effective Dec 17, 2025
Each 25 pre-split shares become 1 post-split share.
Source: EODHD
1 for 20 · reverse split
Effective Jan 22, 2024
Each 20 pre-split shares become 1 post-split share.
Source: EODHD
1 for 7 · reverse split
Effective Dec 23, 2019
Each 7 pre-split shares become 1 post-split share.
Source: EODHD
1 for 7 · reverse split
Effective Dec 8, 2017
Each 7 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if PCSA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
2 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 2, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 4
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
12 filers reported a long position in PCSA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
99%
of the 255.5K shares 13-F filers reported
Moves vs Q1 2026
2 added1 trimmed
4 new · 3 unchanged
Net shares held
+9.6%
across the 6 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | Connective Capital Management, LLC | $163.7K · 85.3K shares | 85.3K | +20.6% |
| 2 | Stonepine Capital Management, LLC | $105.6K · 55K shares | 55K | Unchanged |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | $42.4K · 22.1K shares | 22.1K | -11.3% |
| 4 | CITADEL ADVISORS LLC | $40.9K · 21.3K shares | 21.3K | New |
| 5 | StoneX Group Inc. | $29.6K · 11.4K shares | 11.4K | New |
| 6 | XTX Topco Ltd | $25.5K · 13.3K shares | 13.3K | New |
| 7 | JANE STREET GROUP, LLC | $25.5K · 13.3K shares | 13.3K | New |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | $24.4K · 12.7K shares | 12.7K | Unchanged |
| 9 | VANGUARD FIDUCIARY TRUST CO | $20.8K · 10.9K shares | 10.9K | Unchanged |
| 10 | UBS Group AG | $15K · 7.8K shares | 7.8K | +207.9% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of PCSA file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 18, 2026 | Soleus Capital Master Fund LP13G · passive | 5.8% |
| May 15, 2026 | CVI Investments Inc13G · passive · amended | 7% |
Get the Full Analysis for PCSA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.